TXG

+ Watchlist + Portfolio

10x Genomics, Inc.

Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $88.76
52-Week Range: $11.16 – $95.16
Market Cap: $12.18B
P/E (TTM): —
EPS (TTM): -0.59
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 14.75
PEG Ratio: —
Return on Equity: -9.40%
Return on Assets: -5.05%
Gross Margin: 70.11%
Operating Margin: -15.20%
Profit Margin: -12.18%
Current Ratio: 5.69
Debt/Equity: 0.10
Total Debt: $78.80M
Free Cash Flow: $179.66M
Revenue Growth: -12.70%
Earnings Growth: —
Enterprise Value: $11.71B

TXG Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$516.41M	$618.73M	$610.78M	$642.82M
Cost of Revenue	$120.39M	$209.41M	$196.30M	$198.94M
Gross Profit	$396.02M	$409.31M	$414.48M	$443.88M
Research & Development	$265.67M	$270.33M	$264.70M	$238.63M
Selling, General & Admin	$298.30M	$343.33M	$344.34M	$316.13M
Operating Expenses	$563.97M	$613.66M	$609.04M	$554.77M
Operating Income	-$167.94M	-$204.35M	-$194.56M	-$110.89M
EBITDA	-$128.49M	-$205.11M	-$133.99M	$3.91M
Pretax Income	-$161.97M	-$248.76M	-$177.70M	-$39.91M
Income Tax	$4.03M	$6.34M	$4.93M	$3.64M
Net Income	-$166.00M	-$255.10M	-$182.63M	-$43.54M
Diluted EPS	-1.46	-2.18	-1.52	-0.35
Diluted Shares	113.86M	117.17M	120.45M	124.75M

TXG Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$219.75M	$359.28M	$344.07M	$473.97M
Receivables	$104.21M	$114.83M	$88.47M	$82.49M
Inventory	$81.63M	$73.71M	$83.11M	$56.34M
Current Assets	$635.03M	$596.02M	$584.39M	$684.45M
Total Assets	$1.03B	$965.14M	$918.64M	$1.04B
Current Liabilities	$130.96M	$127.16M	$117.63M	$153.45M
Total Debt	$95.18M	$95.37M	$82.61M	$84.36M
Total Liabilities	$223.24M	$224.10M	$208.50M	$245.04M
Retained Earnings	-$1.03B	-$1.28B	-$1.47B	-$1.51B
Shareholders' Equity	$805.74M	$741.04M	$710.13M	$796.33M
Working Capital	$504.08M	$468.86M	$466.75M	$531.00M

TXG Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$33.61M	-$15.20M	$6.66M	$136.05M
Capital Expenditure	-$131.66M	-$49.52M	-$13.39M	-$5.93M
Free Cash Flow	-$165.27M	-$64.72M	-$6.73M	$130.12M
Depreciation & Amortisation	$33.01M	$43.62M	$43.71M	$43.82M
Stock-Based Compensation	$136.85M	$166.95M	$140.75M	$109.12M
Investing Cash Flow	-$350.89M	$133.49M	-$32.63M	-$13.44M
Financing Cash Flow	$15.82M	$13.67M	$10.91M	$6.80M
Net Change in Cash	-$368.68M	$131.96M	-$15.05M	$129.41M

TXG Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$154.88M	$172.91M	$149.00M	$166.03M	$150.84M	$151.04M
Cost of Revenue	$49.44M	$47.82M	$48.70M	$52.98M	$44.66M	$38.54M
Gross Profit	$105.44M	$125.08M	$100.31M	$113.05M	$106.18M	$112.50M
Research & Development	$64.25M	$61.22M	$57.19M	$55.97M	$56.85M	$56.79M
Selling, General & Admin	$89.73M	$74.43M	$75.36M	$76.62M	$66.38M	$78.66M
Operating Expenses	$153.97M	$135.66M	$132.55M	$132.59M	$123.22M	$135.45M
Operating Income	-$48.53M	-$10.57M	-$32.24M	-$19.54M	-$17.05M	-$22.95M
EBITDA	-$38.71M	$46.65M	-$19.99M	$63.54M	-$5.14M	-$6.96M
Pretax Income	-$33.51M	$37.00M	-$28.20M	-$15.19M	-$12.85M	-$18.64M
Income Tax	$852.00K	$2.46M	-$733.00K	$1.06M	$623.00K	-$714.00K
Net Income	-$34.36M	$34.54M	-$27.47M	-$16.25M	-$13.47M	-$17.93M
Diluted EPS	-0.28	0.28	-0.22	-0.13	-0.10	-0.14
Diluted Shares	122.61M	124.51M	125.50M	127.08M	128.29M	129.98M

TXG Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$377.06M	$397.71M	$432.51M	$473.97M	$490.29M	$502.51M
Receivables	$52.55M	$119.07M	$96.59M	$82.49M	$56.14M	$50.63M
Inventory	$74.71M	$68.97M	$61.96M	$56.34M	$53.49M	$52.62M
Current Assets	$579.73M	$655.66M	$659.83M	$684.45M	$669.73M	$674.67M
Total Assets	$903.39M	$979.97M	$1.03B	$1.04B	$1.02B	$1.03B
Current Liabilities	$107.90M	$112.22M	$147.32M	$153.45M	$113.60M	$118.51M
Total Debt	$80.07M	$86.74M	$86.98M	$84.36M	$81.39M	$78.80M
Total Liabilities	$196.50M	$206.69M	$242.24M	$245.04M	$201.44M	$204.52M
Retained Earnings	-$1.50B	-$1.47B	-$1.49B	-$1.51B	-$1.52B	-$1.54B
Shareholders' Equity	$706.89M	$773.28M	$785.12M	$796.33M	$814.32M	$825.55M
Working Capital	$471.83M	$543.44M	$512.50M	$531.00M	$556.13M	$556.16M

TXG Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$34.35M	$17.71M	$43.21M	$40.78M	$26.12M	$16.97M
Capital Expenditure	-$1.89M	-$1.58M	-$687.00K	-$1.78M	-$1.60M	-$1.59M
Free Cash Flow	$32.46M	$16.13M	$42.53M	$39.00M	$24.52M	$15.39M
Depreciation & Amortisation	$9.81M	$9.65M	$12.25M	$12.10M	$11.91M	$11.68M
Stock-Based Compensation	$31.08M	$27.56M	$25.26M	$25.22M	$22.64M	$25.62M
Investing Cash Flow	-$1.89M	-$939.00K	-$8.80M	-$1.80M	-$1.31M	-$7.74M
Financing Cash Flow	$422.00K	$3.52M	$617.00K	$2.24M	-$8.42M	$3.02M
Net Change in Cash	$32.88M	$20.29M	$35.03M	$41.21M	$16.39M	$12.26M

Market Snapshot

About

10x Genomics develops and manufactures gene sequencing and cell analysis technologies for biological research. The company provides integrated solutions for single-cell analysis, spatial genomics, and in situ analysis, enabling researchers to study complex biological systems at unprecedented resolution.